March 18, 2018 4:09 PM ET

Life Sciences Tools and Services

Company Overview of mBio Diagnostics, Inc.

Company Overview

mBio Diagnostics, Inc. develops clinical diagnostics and sample testing products that deliver on-the-spot results. It offers MBio multiplex analyzers and disposable cartridges that are used for clinical and analytical testing applications in medical, veterinary, environmental, food, agricultural, and military markets. It also provides MBio array systems, which are multiplexed fluorescence immunoassay systems that provide the simultaneous measurement of multiple analytes from a single sample; and LightDeck devices, which are fluorescence assay illumination systems. The company was founded in 2009 and is based in Boulder, Colorado.

5603 Arapahoe Avenueo

Suite 100

Boulder, CO 80301

United States

Founded in 2009





Key Executives for mBio Diagnostics, Inc.

Founder, Chief Executive Officer and Director
Director of Finance & Administration
Chief Technology Officer and Executive Vice President
Compensation as of Fiscal Year 2017.

mBio Diagnostics, Inc. Key Developments

MBio Diagnostics Wins Defense Advanced Research Projects Agency's Phase II Contract for Acute Infection Point-of-Care System

MBio Diagnostics, Inc. announced a contract with the US Defense Advanced Research Projects Agency (DARPA) entitled, “Point-of-care Monitoring of the Host-Pathogen Interaction During Infection.” The Phase II DARPA contract builds on a successful Phase I program focused on development of a portable, multiplexed immunoassay system that rapidly delivers a panel of host response biomarker results. The DARPA project complements MBio’s NIH-funded program entitled “Point-of-Care Prognostic Tool for Sepsis,” which kicked off in September 2017. The NIH program is for development of a prognostic tool to aid in stratifying sepsis patients with highest risk of mortality. The combined value of these contracts, if all phases and options are awarded, is $1.5 million. Both programs are in collaboration with Dr. Hector Wong, Director of the Division of Critical Care Medicine at Cincinnati Children’s Hospital Medical Center.

mBio Diagnostics, Inc. Presents at 5th Biennial Rocky Mountain Life Science Investor and Partnering Conference, Oct-03-2017 11:22 AM

mBio Diagnostics, Inc. Presents at 5th Biennial Rocky Mountain Life Science Investor and Partnering Conference, Oct-03-2017 11:22 AM. Venue: Hotel Talisa, Vail, Colorado, United States.

MBio Diagnostics, Inc. Announces Development Collaboration with Cincinnati Children's Hospital Medical Center

MBio Diagnostics, Inc. announced a product development collaboration with Cincinnati Children's Hospital Medical Center. Researchers at Cincinnati Children's, led by Hector Wong, MD, director, Division of Critical Care Medicine, have been investigating biomarker panels that provide prognostic and predictive patient stratification, particularly in the context of septic shock. MBio will collaborate with Dr. Wong to develop a multi-marker panel to risk stratify patients with septic shock in a clinically relevant time frame. Prognostic and predictive patient stratification are fundamental elements of precision medicine, which seeks to target patient populations in which a drug or intervention is more likely to be effective. Prognostic enrichment strategies select patients with a greater likelihood of having a disease-related event. Predictive enrichment strategies select patients who are more likely to respond to an intervention or drug, based on a biological or physiologic mechanism. Enrichment strategies are particularly effective when selecting patients for treatment trials in highly heterogeneous syndromes, such as septic shock. By using prognostic and predictive strategies in trial design, therapies for critically ill patients can be optimized more quickly. Ultimately this approach will provide precision guidance to therapy in the clinic. In the context of critical care, these precision medicine techniques would ideally be carried out in real-time. The MBio Array System utilizes MBio's proprietary LightDeck technology, which enables simple, multiplex testing in a compact system. This portable, easy-to-use multiplex reader can be placed into a wide variety of clinical situations, including directly placed in the intensive care unit (ICU).

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact mBio Diagnostics, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at